{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:18:43Z","timestamp":1792185523719,"version":"4.4.0"},"reference-count":372,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gerald J. and Dorothy R. Friedman New York Foundation for Medical Research","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cancer, characterized by the uncontrolled proliferation of cells, is one of the leading causes of death globally, with approximately one in five people developing the disease in their lifetime. While many driver genes were identified decades ago, and most cancers can be classified based on morphology and progression, there is still a significant gap in knowledge about genetic aberrations and nuclear DNA damage. The study of two critical groups of genes\u2014tumor suppressors, which inhibit proliferation and promote apoptosis, and oncogenes, which regulate proliferation and survival\u2014can help to understand the genomic causes behind tumorigenesis, leading to more personalized approaches to diagnosis and treatment. Aberration of tumor suppressors, which undergo two-hit and loss-of-function mutations, and oncogenes, activated forms of proto-oncogenes that experience one-hit and gain-of-function mutations, are responsible for the dysregulation of key signaling pathways that regulate cell division, such as p53, Rb, Ras\/Raf\/ERK\/MAPK, PI3K\/AKT, and Wnt\/\u03b2-catenin. Modern breakthroughs in genomics research, like next-generation sequencing, have provided efficient strategies for mapping unique genomic changes that contribute to tumor heterogeneity. Novel therapeutic approaches have enabled personalized medicine, helping address genetic variability in tumor suppressors and oncogenes. This comprehensive review examines the molecular mechanisms behind tumor-suppressor genes and oncogenes, the key signaling pathways they regulate, epigenetic modifications, tumor heterogeneity, and the drug resistance mechanisms that drive carcinogenesis. Moreover, the review explores the clinical application of sequencing techniques, multiomics, diagnostic procedures, pharmacogenomics, and personalized treatment and prevention options, discussing future directions for emerging technologies.<\/jats:p>","DOI":"10.3390\/cancers17061008","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T11:04:22Z","timestamp":1742209462000},"page":"1008","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Translational Advances in Oncogene and Tumor-Suppressor Gene Research"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5942-1622","authenticated-orcid":false,"given":"Radoslav","family":"Stojchevski","sequence":"first","affiliation":[{"name":"Friedman Diabetes Institute, Lenox Hill Hospital, Northwell Health, New York, NY 10022, USA"},{"name":"Feinstein Institutes for Medical Research, Manhasset, NY 11030, USA"},{"name":"Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, NY 11549, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4069-112X","authenticated-orcid":false,"given":"Edward Agus","family":"Sutanto","sequence":"additional","affiliation":[{"name":"CUNY School of Medicine, The City College of New York, 160 Convent Avenue, New York, NY 10031, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinni","family":"Sutanto","sequence":"additional","affiliation":[{"name":"New York Institute of Technology College of Osteopathic Medicine, Glen Head, NY 11545, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-7359","authenticated-orcid":false,"given":"Nikola","family":"Hadzi-Petrushev","sequence":"additional","affiliation":[{"name":"Faculty of Natural Sciences and Mathematics, Institute of Biology, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3475-2131","authenticated-orcid":false,"given":"Mitko","family":"Mladenov","sequence":"additional","affiliation":[{"name":"Faculty of Natural Sciences and Mathematics, Institute of Biology, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajal Raj","family":"Singh","sequence":"additional","affiliation":[{"name":"GloNeuro, Sector 107, Vishwakarma Road, Noida 201301, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-6932","authenticated-orcid":false,"given":"Jitendra Kumar","family":"Sinha","sequence":"additional","affiliation":[{"name":"GloNeuro, Sector 107, Vishwakarma Road, Noida 201301, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3252-7216","authenticated-orcid":false,"given":"Shampa","family":"Ghosh","sequence":"additional","affiliation":[{"name":"GloNeuro, Sector 107, Vishwakarma Road, Noida 201301, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuvaneshwar","family":"Yarlagadda","sequence":"additional","affiliation":[{"name":"GloNeuro, Sector 107, Vishwakarma Road, Noida 201301, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3849-5945","authenticated-orcid":false,"given":"Krishna Kumar","family":"Singh","sequence":"additional","affiliation":[{"name":"Symbiosis Centre for Information Technology (SCIT), Rajiv Gandhi InfoTech Park, Hinjawadi, Pune 411057, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Verma","sequence":"additional","affiliation":[{"name":"School of Management, BML Munjal University, NH8, Sidhrawali, Gurugram 122413, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9710-9576","authenticated-orcid":false,"given":"Sonali","family":"Sengupta","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, All India Institute of Medical Sciences (AIIMS), New Delhi 110029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0181-6197","authenticated-orcid":false,"given":"Rakesh","family":"Bhaskar","sequence":"additional","affiliation":[{"name":"School of Chemical Engineering, Yeungnam University, Gyeongsan 38541, Republic of Korea"},{"name":"Research Institute of Cell Culture, Yeungnam University, Gyeongsan 38541, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4479-6448","authenticated-orcid":false,"given":"Dimiter","family":"Avtanski","sequence":"additional","affiliation":[{"name":"Friedman Diabetes Institute, Lenox Hill Hospital, Northwell Health, New York, NY 10022, USA"},{"name":"Feinstein Institutes for Medical Research, Manhasset, NY 11030, USA"},{"name":"Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, NY 11549, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4103\/0019-509X.200658","article-title":"Cancer and Cure: A Critical Analysis","volume":"53","author":"Roy","year":"2016","journal-title":"Indian J. Cancer"},{"key":"ref_2","unstructured":"International Agency for Research on Cancer (IARC) (2025, January 05). Cancer Factsheets. Available online: https:\/\/gco.iarc.fr\/today\/en\/fact-sheets-cancers."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cell.2011.03.019","article-title":"Mapping Cancer Origins","volume":"145","author":"Gilbertson","year":"2011","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1038\/sj.onc.1209604","article-title":"Mitochondrial DNA Mutations in Human Cancer","volume":"25","author":"Chatterjee","year":"2006","journal-title":"Oncogene"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.trecan.2022.08.001","article-title":"Mitochondrial DNA Is a Major Source of Driver Mutations in Cancer","volume":"8","author":"Kim","year":"2022","journal-title":"Trends Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1002\/1873-3468.13781","article-title":"Understanding Oncogenicity of Cancer Driver Genes and Mutations in the Cancer Genomics Era","volume":"594","author":"Valencia","year":"2020","journal-title":"FEBS Lett."},{"key":"ref_7","first-page":"1061","article-title":"Oncogenes and Tumor-Suppressor Genes in Mesothelioma\u2014A Synopsis","volume":"105","author":"Lechner","year":"1997","journal-title":"Environ. Health Perspect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e582","DOI":"10.1002\/mco2.582","article-title":"Oncogenes and Tumor Suppressor Genes: Functions and Roles in Cancers","volume":"5","author":"Dakal","year":"2024","journal-title":"MedComm"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.68.4.820","article-title":"Mutation and Cancer: Statistical Study of Retinoblastoma","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41467-020-16399-y","article-title":"Loss of Heterozygosity of Essential Genes Represents a Widespread Class of Potential Cancer Vulnerabilities","volume":"11","author":"Nichols","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s00018-003-3043-6","article-title":"Killing Cancer by Targeting Genes That Cancer Cells Have Lost: Allele-Specific Inhibition, a Novel Approach to the Treatment of Genetic Disorders","volume":"60","author":"Fluiter","year":"2003","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0897.1991.tb01080.x","article-title":"Proto-Oncogenes in Development and Cancer","volume":"25","author":"Torry","year":"1991","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00043426-199505000-00003","article-title":"Oncogenes, Protooncogenes, and Tumor Suppressor Genes in Acute Myelogenous Leukemia","volume":"17","author":"Hijiya","year":"1995","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.4161\/cc.25690","article-title":"Heritable One-Hit Events Defining Cancer Prevention?","volume":"12","author":"Kopelovich","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7051","DOI":"10.1038\/s41467-021-27242-3","article-title":"Higher Order Genetic Interactions Switch Cancer Genes from Two-Hit to One-Hit Drivers","volume":"12","author":"Park","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_16","first-page":"21","article-title":"Historical Retrospective of the SRC Oncogene and New Perspectives (Review)","volume":"13","author":"Simatou","year":"2020","journal-title":"Mol. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.21873\/anticanres.14622","article-title":"Role of Oncogenes and Tumor-Suppressor Genes in Carcinogenesis: A Review","volume":"40","author":"Kontomanolis","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Roy, S., Bondada, M.S., Zhang, Y., Moffat, K., Nair, V., and Yao, Y. (2022). Proviral ALV-LTR Sequence Is Essential for Continued Proliferation of the ALV-Transformed B Cell Line. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911263"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12935-022-02761-1","article-title":"HER2 Amplification by Next-Generation Sequencing to Identify HER2-Positive Invasive Breast Cancer with Negative HER2 Immunohistochemistry","volume":"22","author":"Morsberger","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2159-8290.CD-17-0993","article-title":"MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification","volume":"8","author":"Zimmerman","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gariglio, P. (2012). Oncogenes and Tumor Suppressor Genes. Molecular Oncology: Principles and Recent Advances, Bentham Science Publishers.","DOI":"10.2174\/978160805016111201010064"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A Comprehensive Survey of Ras Mutations in Cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/14796694.5.1.105","article-title":"Isoform-Specific Ras Functions in Development and Cancer","volume":"5","author":"Quinlan","year":"2009","journal-title":"Future Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hutter, S., Bolin, S., Weishaupt, H., and Swartling, F. (2017). Modeling and Targeting MYC Genes in Childhood Brain Tumors. Genes, 8.","DOI":"10.3390\/genes8040107"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11382","DOI":"10.1074\/jbc.AW119.008149","article-title":"Dissecting the Mechanisms of Cell Division","volume":"294","author":"Ong","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1073\/pnas.87.12.4766","article-title":"Human P53 Is Phosphorylated by P60-Cdc2 and Cyclin B-Cdc2","volume":"87","author":"Bischoff","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4161\/cbt.19589","article-title":"Cyclin Dependent Kinases in Cancer","volume":"13","author":"Canavese","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"\u0141ukasik, P., Za\u0142uski, M., and Gutowska, I. (2021). Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development-Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22062935"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Cao, L., Chen, F., Yang, X., Xu, W., Xie, J., and Yu, L. (2014). Phylogenetic Analysis of CDK and Cyclin Proteins in Premetazoan Lineages. BMC Evol. Biol., 14.","DOI":"10.1186\/1471-2148-14-10"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ding, L., Cao, J., Lin, W., Chen, H., Xiong, X., Ao, H., Yu, M., Lin, J., and Cui, Q. (2020). The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21061960"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12935-022-02747-z","article-title":"A Review on the Role of Cyclin Dependent Kinases in Cancers","volume":"22","author":"Khoshbakht","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The History and Future of Targeting Cyclin-Dependent Kinases in Cancer Therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/35106065","article-title":"To Cycle or Not to Cycle: A Critical Decision in Cancer","volume":"1","author":"Malumbres","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.molcel.2019.03.020","article-title":"Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein\u2019s C-Terminal Helix","volume":"74","author":"Topacio","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1006\/jmbi.1999.2640","article-title":"Mechanisms of Cyclin-Dependent Kinase Regulation: Structures of Cdks, Their Cyclin Activators, and Cip and INK4 Inhibitors","volume":"287","author":"Pavletich","year":"1999","journal-title":"J. Mol. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Fagundes, R., and Teixeira, L.K. (2021). Cyclin E\/CDK2: DNA Replication, Replication Stress and Genomic Instability. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.774845"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev.cellbio.13.1.261","article-title":"CYCLIN-DEPENDENT KINASES: Engines, Clocks, and Microprocessors","volume":"13","author":"Morgan","year":"1997","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"M123","DOI":"10.1016\/S0304-419X(01)00019-1","article-title":"Regulation of the Retinoblastoma Tumor Suppressor Protein by Cyclin\/Cdks","volume":"1471","author":"Adams","year":"2001","journal-title":"Biochim. Biophys. Acta-Rev. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.molcel.2020.08.020","article-title":"Integrating Old and New Paradigms of G1\/S Control","volume":"80","author":"Rubin","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Tamrakar, S. (2000). Role of PRB Dephosphorylation in Cell Cycle Regulation. Front. Biosci., 5.","DOI":"10.2741\/Tamrakar"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in Cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7847","DOI":"10.1038\/s41467-023-43716-y","article-title":"Non-Canonical Pathway for Rb Inactivation and External Signaling Coordinate Cell-Cycle Entry without CDK4\/6 Activity","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez Borrero, L.J., and El-Deiry, W.S. (2021). Tumor Suppressor P53: Biology, Signaling Pathways, and Therapeutic Targeting. Biochim. Biophys. Acta-Rev. Cancer, 1876.","DOI":"10.1016\/j.bbcan.2021.188556"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting P53 Pathways: Mechanisms, Structures and Advances in Therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell Cycle Regulation: P53-P21-RB Signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death Differ."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0955-0674(02)00388-5","article-title":"A Revised Picture of the E2F Transcriptional Network and RB Function","volume":"14","author":"Stevaux","year":"2002","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrc3711","article-title":"Unravelling Mechanisms of P53-Mediated Tumour Suppression","volume":"14","author":"Bieging","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12935-019-0937-4","article-title":"The Role of MDM2 Amplification and Overexpression in Therapeutic Resistance of Malignant Tumors","volume":"19","author":"Hou","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41392-022-01107-7","article-title":"P53 Positively Regulates the Proliferation of Hepatic Progenitor Cells Promoted by Laminin-521","volume":"7","author":"Ma","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1097-2765(03)00050-9","article-title":"P53 Has a Direct Apoptogenic Role at the Mitochondria","volume":"11","author":"Mihara","year":"2003","journal-title":"Mol. Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.tig.2022.02.010","article-title":"The P53 Network: Cellular and Systemic DNA Damage Responses in Cancer and Aging","volume":"38","author":"Vaddavalli","year":"2022","journal-title":"Trends Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/cdd.2017.169","article-title":"How Does P53 Induce Apoptosis and How Does This Relate to P53-Mediated Tumour Suppression?","volume":"25","author":"Aubrey","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Sinha, A., Zou, Y., Patel, A.S., Yoo, S., Jiang, F., Sato, T., Kong, R., Watanabe, H., Zhu, J., and Massion, P.P. (2022). Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted Therapy. Cancers, 14.","DOI":"10.3390\/cancers14030708"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Martinez-Monleon, A., Kryh \u00d6berg, H., Gaarder, J., Berbegall, A.P., Javanmardi, N., Djos, A., Ussowicz, M., Taschner-Mandl, S., Ambros, I.M., and \u00d8ra, I. (2022). Amplification of CDK4 and MDM2: A Detailed Study of a High-Risk Neuroblastoma Subgroup. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-16455-1"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1093\/carcin\/bgt138","article-title":"Aneuploidy, Oncogene Amplification and Epithelial to Mesenchymal Transition Define Spontaneous Transformation of Murine Epithelial Cells","volume":"34","author":"McNeil","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1210\/endrev\/bnad008","article-title":"Signaling Pathways of the Insulin-like Growth Factor Binding Proteins","volume":"44","author":"Baxter","year":"2023","journal-title":"Endocr. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1158\/1078-0432.CCR-03-0497","article-title":"Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate Cancer","volume":"10","author":"Bianco","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"53968","DOI":"10.18632\/oncotarget.16345","article-title":"MDM2 Antagonists Synergize with PI3K\/MTOR Inhibition in Well-Differentiated\/Dedifferentiated Liposarcomas","volume":"8","author":"Laroche","year":"2017","journal-title":"Oncotarget"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e2003193118","DOI":"10.1073\/pnas.2003193118","article-title":"Mdm2 Phosphorylation by Akt Regulates the P53 Response to Oxidative Stress to Promote Cell Proliferation and Tumorigenesis","volume":"118","author":"Chibaya","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/cdd.2009.67","article-title":"Ubiquitin-Independent P53 Proteasomal Degradation","volume":"17","author":"Tsvetkov","year":"2010","journal-title":"Cell Death Differ."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"jcs259114","DOI":"10.1242\/jcs.259114","article-title":"Reciprocal Regulation of P21 and Chk1 Controls the Cyclin D1-RB Pathway to Mediate Senescence Onset after G2 Arrest","volume":"135","author":"Lossaint","year":"2022","journal-title":"J. Cell Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41419-019-1616-z","article-title":"Thr55 Phosphorylation of P21 by MPK38\/MELK Ameliorates Defects in Glucose, Lipid, and Energy Metabolism in Diet-Induced Obese Mice","volume":"10","author":"Seong","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1101\/gad.1103603","article-title":"Integral Role of Noxa in P53-Mediated Apoptotic Response","volume":"17","author":"Shibue","year":"2003","journal-title":"Genes Dev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1097-2765(01)00214-3","article-title":"PUMA, a Novel Proapoptotic Gene, Is Induced by P53","volume":"7","author":"Nakano","year":"2001","journal-title":"Mol. Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41419-021-03902-6","article-title":"Puma, Noxa, P53, and P63 Differentially Mediate Stress Pathway Induced Apoptosis","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/molehr\/4.12.1099","article-title":"The Relationship between BcI2, Bax and P53: Consequences for Cell Cycle Progression and Cell Death","volume":"4","author":"Basu","year":"1998","journal-title":"Mol. Hum. Reprod."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Xu, J., Wang, X., Zhu, C., and Wang, K. (2022). A Review of Current Evidence about LncRNA MEG3: A Tumor Suppressor in Multiple Cancers. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.997633"},{"key":"ref_68","first-page":"1997","article-title":"ERK\/MAPK Signalling Pathway and Tumorigenesis (Review)","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_69","first-page":"113","article-title":"An Update on the Biology of RAS\/RAF Mutations in Colorectal Cancer","volume":"7","author":"Nandan","year":"2011","journal-title":"Curr. Color. Cancer Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/sj.onc.1202174","article-title":"Increasing Complexity of Ras Signaling","volume":"17","author":"Campbell","year":"1998","journal-title":"Oncogene"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Osaka, N., Hirota, Y., Ito, D., Ikeda, Y., Kamata, R., Fujii, Y., Chirasani, V.R., Campbell, S.L., Takeuchi, K., and Senda, T. (2021). Divergent Mechanisms Activating RAS and Small GTPases Through Post-Translational Modification. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.707439"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK Pathway for Cancer Therapy: From Mechanism to Clinical Studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1556-0864(15)31506-9","article-title":"The Ras\/Raf\/MAPK Pathway","volume":"1","author":"Molina","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1111\/febs.16433","article-title":"Understanding the Interaction of 14-3-3 Proteins with h DMX and h DM2: A Structural and Biophysical Study","volume":"289","author":"Wolter","year":"2022","journal-title":"FEBS J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.3892\/ol.2016.5110","article-title":"The Ras\/Raf\/MEK\/ERK Signaling Pathway and Its Role in the Occurrence and Development of HCC","volume":"12","author":"Li","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0092-8674(91)90098-J","article-title":"ERKs: A Family of Protein-Serine\/Threonine Kinases That Are Activated and Tyrosine Phosphorylated in Response to Insulin and NGF","volume":"65","author":"Boulton","year":"1991","journal-title":"Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS Mutation: From Undruggable to Druggable in Cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-Targeted Therapies: Is the Undruggable Drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"\u015amiech, M., Leszczy\u0144ski, P., Kono, H., Wardell, C., and Taniguchi, H. (2020). Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks. Genes, 11.","DOI":"10.3390\/genes11111342"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/1535-7163.MCT-10-0799","article-title":"BRAFV600E: Implications for Carcinogenesis and Molecular Therapy","volume":"10","author":"Sheils","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"\u015amiech, M., Leszczy\u0144ski, P., Wardell, C., Pozna\u0144ski, P., Pierzcha\u0142a, M., and Taniguchi, H. (2022). Oncogenic Mutation BRAF V600E Changes Phenotypic Behavior of THLE-2 Liver Cells through Alteration of Gene Expression. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031548"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13046-020-01709-5","article-title":"The Role of Microenvironment in Tumor Angiogenesis","volume":"39","author":"Jiang","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"175586","DOI":"10.1016\/j.ejphar.2023.175586","article-title":"The Role of VEGF in Cancer-Induced Angiogenesis and Research Progress of Drugs Targeting VEGF","volume":"949","author":"Ghalehbandi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt Signal Transduction for Cancer Therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The Emerging Mechanisms of Isoform-Specific PI3K Signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","article-title":"PI3K\/AKT Pathway as a Key Link Modulates the Multidrug Resistance of Cancers","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT Pathway for Cancer Drug Discovery","volume":"4","author":"Hennessy","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Habrowska-G\u00f3rczy\u0144ska, D.E., Kozie\u0142, M.J., Urbanek, K.A., Kowalska, K., and Piastowska-Ciesielska, A.W. (2024). FOXO3a\/PI3K\/Akt Pathway Participates in the ROS- Induced Apoptosis Triggered by \u03b1-ZEL and \u03b2-ZEL. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-64350-8"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/MTOR Signaling Transduction Pathway and Targeted Therapies in Cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","article-title":"Multifaceted Role of MTOR (Mammalian Target of Rapamycin) Signaling Pathway in Human Health and Disease","volume":"8","author":"Panwar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Zou, Z., Tao, T., Li, H., and Zhu, X. (2020). MTOR Signaling Pathway and MTOR Inhibitors in Cancer: Progress and Challenges. Cell Biosci., 10.","DOI":"10.1186\/s13578-020-00396-1"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1038\/ncomms6416","article-title":"The MTORC1 Effectors S6K1 and 4E-BP Play Different Roles in CNS Axon Regeneration","volume":"5","author":"Yang","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.molcel.2021.01.033","article-title":"Regulation of PTEN Translation by PI3K Signaling Maintains Pathway Homeostasis","volume":"81","author":"Mukherjee","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1759091415602463","DOI":"10.1177\/1759091415602463","article-title":"Crosstalk Between MAPK\/ERK and PI3K\/AKT Signal Pathways During Brain Ischemia\/Reperfusion","volume":"7","author":"Zhou","year":"2015","journal-title":"ASN Neuro"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/glia.22729","article-title":"Interaction of MTOR and Erk1\/2 Signaling to Regulate Oligodendrocyte Differentiation","volume":"62","author":"Dai","year":"2014","journal-title":"Glia"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/\u03b2-Catenin Signaling Pathway in Cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Anand, A.A., Khan, M., Monica, V., and Kar, D. (2023). The Molecular Basis of Wnt\/\u03b2-Catenin Signaling Pathways in Neurodegenerative Diseases. Int. J. Cell Biol., 2023.","DOI":"10.1155\/2023\/9296092"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Stamos, J.L., and Weis, W.I. (2013). The \u03b2-Catenin Destruction Complex. Cold Spring Harb. Perspect. Biol., 5.","DOI":"10.1101\/cshperspect.a007898"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"MacDonald, B.T., and He, X. (2012). Frizzled and LRP5\/6 Receptors for Wnt\/\u03b2-Catenin Signaling. Cold Spring Harb. Perspect. Biol., 4.","DOI":"10.1101\/cshperspect.a007880"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Cadigan, K.M., and Waterman, M.L. (2012). TCF\/LEFs and Wnt Signaling in the Nucleus. Cold Spring Harb. Perspect. Biol., 4.","DOI":"10.1101\/cshperspect.a007906"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/modpathol.3880196","article-title":"Mutational Analysis of the CTNNB1 and APC Genes in Uterine Endometrioid Carcinoma","volume":"13","author":"Schlosshauer","year":"2000","journal-title":"Mod. Pathol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1158\/1541-7786.MCR-21-0666","article-title":"MYC Hyperactivates Wnt Signaling in APC\/CTNNB1-Mutated Colorectal Cancer Cells through MiR-92a\u2013Dependent Repression of DKK3","volume":"19","author":"Sehgal","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00018-023-05099-7","article-title":"Wnt\/\u03b2-Catenin-Driven EMT Regulation in Human Cancers","volume":"81","author":"Xue","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3892\/ijo.2016.3337","article-title":"WNT Pathway Inhibitor Pyrvinium Pamoate Inhibits the Self-Renewal and Metastasis of Breast Cancer Stem Cells","volume":"48","author":"Xu","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"110350","DOI":"10.1016\/j.cellsig.2022.110350","article-title":"Crosstalk between PI3K\/AKT\/MTOR and WNT\/\u03b2-Catenin Signaling in GBM\u2014Could Combination Therapy Checkmate the Collusion?","volume":"95","author":"Biswas","year":"2022","journal-title":"Cell. Signal."},{"key":"ref_106","first-page":"1","article-title":"Crosstalk between PI3K\/Akt and Wnt\/\u03b2-Catenin Pathways Promote Colorectal Cancer Progression Regardless of Mutational Status","volume":"23","author":"Rocha","year":"2022","journal-title":"Cancer Biol. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1182\/blood.V122.21.4886.4886","article-title":"PI3K\/Akt Signaling Interacts with Wnt\/\u03b2-Catenin Signaling But Does Not Induce an Accumulation of \u03b2-Catenin in the Nucleus of Acute Lymphoblastic Leukemia Cell Lines","volume":"122","author":"Langhammer","year":"2013","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e02792-21","DOI":"10.1128\/mBio.02792-21","article-title":"Heparanase-Induced Activation of AKT Stabilizes \u03b2-Catenin and Modulates Wnt\/\u03b2-Catenin Signaling during Herpes Simplex Virus 1 Infection","volume":"12","author":"Koujah","year":"2021","journal-title":"MBio"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"11221","DOI":"10.1074\/jbc.M611871200","article-title":"Phosphorylation of \u03b2-Catenin by AKT Promotes \u03b2-Catenin Transcriptional Activity","volume":"282","author":"Fang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41698-018-0049-y","article-title":"Interaction between Wnt\/\u03b2-Catenin and RAS-ERK Pathways and an Anti-Cancer Strategy via Degradations of \u03b2-Catenin and RAS by Targeting the Wnt\/\u03b2-Catenin Pathway","volume":"2","author":"Jeong","year":"2018","journal-title":"npj Precis. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00441-014-2010-x","article-title":"A Review of Crosstalk between MAPK and Wnt Signals and Its Impact on Cartilage Regeneration","volume":"358","author":"Zhang","year":"2014","journal-title":"Cell Tissue Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/carcin\/bgp220","article-title":"Epigenetics in Cancer","volume":"31","author":"Sharma","year":"2010","journal-title":"Carcinogenesis"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg816","article-title":"The Fundamental Role of Epigenetic Events in Cancer","volume":"3","author":"Jones","year":"2002","journal-title":"Nat. Rev. Genet."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","article-title":"Epigenetics in Human Disease and Prospects for Epigenetic Therapy","volume":"429","author":"Egger","year":"2004","journal-title":"Nature"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1002\/ctd2.279","article-title":"Role of DNA Methylation in Cancer Development and Its Clinical Applications","volume":"4","author":"Sonar","year":"2024","journal-title":"Clin. Transl. Discov."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Lakshminarasimhan, R., and Liang, G. (2016). The Role of DNA Methylation in Cancer. DNA Methyltransferases-Role and Function, Springer.","DOI":"10.1007\/978-3-319-43624-1_7"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Stojchevski, R., Velichkovikj, S., and Arsov, T. (2023). Genetic and Epigenetic Basis of Obesity-Induced Inflammation and Diabetes. Obesity, Diabetes and Inflammation: Molecular Mechanisms and Clinical Management, Springer.","DOI":"10.1007\/978-3-031-39721-9_6"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","article-title":"Navigating the DNA Methylation Landscape of Cancer","volume":"37","author":"Nishiyama","year":"2021","journal-title":"Trends Genet."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10238-017-0467-0","article-title":"DNA Methylation Profiles in Cancer Diagnosis and Therapeutics","volume":"18","author":"Pan","year":"2018","journal-title":"Clin. Exp. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/15592294.2019.1638701","article-title":"DNA Hypermethylation in Disease: Mechanisms and Clinical Relevance","volume":"14","author":"Ehrlich","year":"2019","journal-title":"Epigenetics"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3748\/wjg.v13.i12.1767","article-title":"Microsatellite Instability and MLH1 Promoter Hypermethylation in Colorectal Cancer","volume":"13","author":"Niv","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Oubaddou, Y., Oukabli, M., Fenniche, S., Elktaibi, A., Elochi, M.R., Al Bouzidi, A., Qmichou, Z., Dakka, N., Diorio, C., and Richter, A. (2023). BRCA1 Promoter Hypermethylation in Malignant Breast Tumors and in the Histologically Normal Adjacent Tissues to the Tumors: Exploring Its Potential as a Biomarker and Its Clinical Significance in a Translational Approach. Genes, 14.","DOI":"10.3390\/genes14091680"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Tramontano, A., Boffo, F.L., Russo, G., De Rosa, M., Iodice, I., and Pezone, A. (2020). Methylation of the Suppressor Gene P16INK4a: Mechanism and Consequences. Biomolecules, 10.","DOI":"10.3390\/biom10030446"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Besselink, N., Keijer, J., Vermeulen, C., Boymans, S., de Ridder, J., van Hoeck, A., Cuppen, E., and Kuijk, E. (2023). The Genome-Wide Mutational Consequences of DNA Hypomethylation. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-33932-3"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/carcin\/bgp143","article-title":"Association between Global DNA Hypomethylation in Leukocytes and Risk of Breast Cancer","volume":"30","author":"Choi","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s11033-021-06227-x","article-title":"Promoter Hypomethylation as Potential Confounder of Ras Gene Overexpression and Their Clinical Significance in Subsets of Urothelial Carcinoma of Bladder","volume":"48","author":"Tripathi","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2217\/epi.09.33","article-title":"Dna Hypomethylation In Cancer Cells","volume":"1","author":"Ehrlich","year":"2009","journal-title":"Epigenomics"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Fain, J.S., Loriot, A., Diacofotaki, A., Van Tongelen, A., and De Smet, C. (2021). Transcriptional Overlap Links DNA Hypomethylation with DNA Hypermethylation at Adjacent Promoters in Cancer. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-96844-0"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Zhao, Z., and Shilatifard, A. (2019). Epigenetic Modifications of Histones in Cancer. Genome Biol., 20.","DOI":"10.1186\/s13059-019-1870-5"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/978-94-007-4525-4_13","article-title":"The Role of DNA Methylation and Histone Modifications in Transcriptional Regulation in Humans","volume":"61","author":"Miller","year":"2013","journal-title":"Subcell. Biochem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.184.4139.868","article-title":"Chromatin Structure: A Repeating Unit of Histones and DNA","volume":"184","author":"Kornberg","year":"1974","journal-title":"Science"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13223-018-0259-4","article-title":"Histone Modifications and Their Role in Epigenetics of Atopy and Allergic Diseases","volume":"14","author":"Khalaila","year":"2018","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Arif, K.M.T., Elliott, E.K., Haupt, L.M., and Griffiths, L.R. (2020). Regulatory Mechanisms of Epigenetic MiRNA Relationships in Human Cancer and Potential as Therapeutic Targets. Cancers, 12.","DOI":"10.3390\/cancers12102922"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"24790","DOI":"10.1074\/jbc.M604175200","article-title":"Tumor Suppressor P16INK4A Regulates Polycomb-Mediated DNA Hypermethylation in Human Mammary Epithelial Cells","volume":"281","author":"Reynolds","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"a026575","DOI":"10.1101\/cshperspect.a026575","article-title":"Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer","volume":"6","author":"Laugesen","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1172\/JCI96520","article-title":"Cyclin D1 Overexpression Induces Global Transcriptional Downregulation in Lymphoid Neoplasms","volume":"128","author":"Albero","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Braile, M., Luciano, N., Carlomagno, D., Salvatore, G., and Orlandella, F.M. (2024). Insight into the Role of the MiR-584 Family in Human Cancers. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25137448"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent Deletions and Down-Regulation of Micro- RNA Genes MiR15 and MiR16 at 13q14 in Chronic Lymphocytic Leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Torres, A., Torres, K., Pesci, A., Ceccaroni, M., Paszkowski, T., Cassandrini, P., Zamboni, G., and Maciejewski, R. (2012). Deregulation of MiR-100, MiR-99a and MiR-199b in Tissues and Plasma Coexists with Increased Expression of MTOR Kinase in Endometrioid Endometrial Carcinoma. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-369"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13046-016-0432-x","article-title":"Upregulation of MiR-501-5p Activates the Wnt\/\u03b2-Catenin Signaling Pathway and Enhances Stem Cell-like Phenotype in Gastric Cancer","volume":"35","author":"Fan","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijrobp.2010.12.049","article-title":"MicroRNA-221 and -222 Regulate Radiation Sensitivity by Targeting the PTEN Pathway","volume":"80","author":"Zhang","year":"2011","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Ma, Y., Shen, N., Wicha, M.S., and Luo, M. (2021). The Roles of the Let-7 Family of MicroRNAs in the Regulation of Cancer Stemness. Cells, 10.","DOI":"10.3390\/cells10092415"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.21037\/atm-21-1948","article-title":"A Narrative Review of Tumor Heterogeneity and Challenges to Tumor Drug Therapy","volume":"9","author":"Zhu","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour Heterogeneity and Resistance to Cancer Therapies","volume":"15","author":"Shaw","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1038\/emm.2017.165","article-title":"The Significance of Intertumor and Intratumor Heterogeneity in Liver Cancer","volume":"50","author":"Liu","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the Evolution of Non\u2013Small-Cell Lung Cancer","volume":"376","author":"Wilson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nature09460","article-title":"The Patterns and Dynamics of Genomic Instability in Metastatic Pancreatic Cancer","volume":"467","author":"Campbell","year":"2010","journal-title":"Nature"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e1338","DOI":"10.1002\/ctm2.1338","article-title":"Integrated Single-Cell and Spatial Transcriptomic Profiling Reveals Higher Intratumour Heterogeneity and Epithelial-Fibroblast Interactions in Recurrent Bladder Cancer","volume":"13","author":"Shi","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/ng.3838","article-title":"Spatial Heterogeneity in Medulloblastoma","volume":"49","author":"Morrissy","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nm.3984","article-title":"Pan-Cancer Analysis of the Extent and Consequences of Intratumor Heterogeneity","volume":"22","author":"Andor","year":"2016","journal-title":"Nat. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Fu, F., Nowak, M.A., and Bonhoeffer, S. (2015). Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy. PLoS Comput. Biol., 11.","DOI":"10.1371\/journal.pcbi.1004142"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"216350","DOI":"10.1016\/j.canlet.2023.216350","article-title":"Spatio-Temporal Heterogeneity in Cancer Evolution and Tumor Microenvironment of Renal Cell Carcinoma with Tumor Thrombus","volume":"572","author":"Zhou","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_154","first-page":"601","article-title":"Chromosome 9p Deletions Are an Independent Predictor of Tumor Progression Following Nephrectomy in Patients with Localized Clear Cell Renal Cell Carcinoma","volume":"32","author":"Reis","year":"2014","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cam4.351","article-title":"Downregulation of NDUFB6 Due to 9p24.1-p13.3 Loss Is Implicated in Metastatic Clear Cell Renal Cell Carcinoma","volume":"4","author":"Narimatsu","year":"2015","journal-title":"Cancer Med."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Whitlock, B.D., and Leslie, E.M. (2020). Efflux Transporters in Anti-Cancer Drug Resistance: Molecular and Functional Identification and Characterization of Multidrug Resistance Proteins (MRPs\/ABCCs). Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy, Elsevier.","DOI":"10.1016\/B978-0-12-816434-1.00002-4"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The Different Mechanisms of Cancer Drug Resistance: A Brief Review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharm. Bull."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Ashique, S., Bhowmick, M., Pal, R., Khatoon, H., Kumar, P., Sharma, H., Garg, A., Kumar, S., and Das, U. (2024). Multi Drug Resistance in Colorectal Cancer-Approaches to Overcome, Advancements and Future Success. Adv. Cancer Biol.-Metastasis, 10.","DOI":"10.1016\/j.adcanc.2024.100114"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pccm.2023.07.001","article-title":"Role of C-Myc in Lung Cancer: Progress, Challenges, and Prospects","volume":"1","author":"Wallbillich","year":"2023","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Al-Abdulla, R., Perez-Silva, L., Lozano, E., Macias, R.I.R., Herraez, E., Abad, M., Segues, N., Bujanda, L., Briz, O., and Marin, J.J.G. (2020). Sensitizing Gastric Adenocarcinoma to Chemotherapy by Pharmacological Manipulation of Drug Transporters. Biochem. Pharmacol., 171.","DOI":"10.1016\/j.bcp.2019.113682"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the Breast Cancer Resistance Protein (BCRP\/ABCG2) in Drug Transport\u2014An Update","volume":"17","author":"Mao","year":"2015","journal-title":"AAPS J."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"eabp9530","DOI":"10.1126\/sciadv.abp9530","article-title":"BCRP Drives Intrinsic Chemoresistance in Chemotherapy-Na\u00efve Breast Cancer Brain Metastasis","volume":"9","author":"Margarido","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1016\/j.molcel.2022.11.008","article-title":"POLQ Seals Post-Replicative SsDNA Gaps to Maintain Genome Stability in BRCA-Deficient Cancer Cells","volume":"82","author":"Belan","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"13390","DOI":"10.1073\/pnas.0910759107","article-title":"DNA Polymerase \u03b8 up-Regulation Is Associated with Poor Survival in Breast Cancer, Perturbs DNA Replication, and Promotes Genetic Instability","volume":"107","author":"Bergoglio","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"175","DOI":"10.18632\/oncotarget.124","article-title":"Overexpression of POLQ Confers a Poor Prognosis in Early Breast Cancer Patients","volume":"1","author":"Higgins","year":"2010","journal-title":"Oncotarget"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The Multifaceted Roles of PARP1 in DNA Repair and Chromatin Remodelling","volume":"18","author":"Nussenzweig","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/annonc\/mdr361","article-title":"Nuclear PARP-1 Protein Overexpression Is Associated with Poor Overall Survival in Early Breast Cancer","volume":"23","author":"Rojo","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Gilabert, M., Launay, S., Ginestier, C., Bertucci, F., Audebert, S., Pophillat, M., Toiron, Y., Baudelet, E., Finetti, P., and Noguchi, T. (2014). Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0104302"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/1947601910383418","article-title":"Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types","volume":"1","author":"Ossovskaya","year":"2010","journal-title":"Genes Cancer"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.1007\/s13277-015-4465-0","article-title":"Nuclear PARP1 Expression and Its Prognostic Significance in Breast Cancer Patients","volume":"37","author":"Mazzotta","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Wang, F., Gouttia, O.G., Wang, L., and Peng, A. (2022). PARP1 Upregulation in Recurrent Oral Cancer and Treatment Resistance. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.804962"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1038\/s41467-021-23463-8","article-title":"Pol\u03b8 Inhibitors Elicit BRCA-Gene Synthetic Lethality and Target PARP Inhibitor Resistance","volume":"12","author":"Zatreanu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e165934","DOI":"10.1172\/JCI165934","article-title":"POLQ Inhibition Elicits an Immune Response in Homologous Recombination\u2013Deficient Pancreatic Adenocarcinoma via CGAS\/STING Signaling","volume":"133","author":"Oh","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Liu, P., Hao, L., Liu, M., and Hu, S. (2023). Glutathione-Responsive and -Exhausting Metal Nanomedicines for Robust Synergistic Cancer Therapy. Front. Bioeng. Biotechnol., 11.","DOI":"10.3389\/fbioe.2023.1161472"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Niu, B., Liao, K., Zhou, Y., Wen, T., Quan, G., Pan, X., and Wu, C. (2021). Application of Glutathione Depletion in Cancer Therapy: Enhanced ROS-Based Therapy, Ferroptosis, and Chemotherapy. Biomaterials, 277.","DOI":"10.1016\/j.biomaterials.2021.121110"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2008.08.006","article-title":"Glutathione: Overview of Its Protective Roles, Measurement, and Biosynthesis","volume":"30","author":"Forman","year":"2009","journal-title":"Mol. Asp. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jconrel.2019.12.040","article-title":"Modulating Intracellular Oxidative Stress via Engineered Nanotherapeutics","volume":"319","author":"Hu","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"972913","DOI":"10.1155\/2013\/972913","article-title":"Role of Glutathione in Cancer Progression and Chemoresistance","volume":"2013","author":"Traverso","year":"2013","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature16967","article-title":"Mutant Kras Copy Number Defines Metabolic Reprogramming and Therapeutic Susceptibilities","volume":"531","author":"Kerr","year":"2016","journal-title":"Nature"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.canlet.2020.02.015","article-title":"Ferroptosis, a Novel Pharmacological Mechanism of Anti-Cancer Drugs","volume":"483","author":"Su","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Yan, H., Talty, R., Jain, A., Cai, Y., Zheng, J., Shen, X., Muca, E., Paty, P.B., Bosenberg, M.W., and Khan, S.A. (2023). Discovery of Decreased Ferroptosis in Male Colorectal Cancer Patients with KRAS Mutations. Redox Biol., 62.","DOI":"10.1016\/j.redox.2023.102699"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Pupo, E., Avanzato, D., Middonti, E., Bussolino, F., and Lanzetti, L. (2019). KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00848"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Datta, N., Chakraborty, S., Basu, M., and Ghosh, M.K. (2020). Tumor Suppressors Having Oncogenic Functions: The Double Agents. Cells, 10.","DOI":"10.3390\/cells10010046"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Stein, Y., Rotter, V., and Aloni-Grinstein, R. (2019). Gain-of-Function Mutant P53: All the Roads Lead to Tumorigenesis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246197"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41586-020-2541-0","article-title":"The Gut Microbiome Switches Mutant P53 from Tumour-Suppressive to Oncogenic","volume":"586","author":"Kadosh","year":"2020","journal-title":"Nature"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"a014407","DOI":"10.1101\/cshperspect.a014407","article-title":"MYC and the Control of Apoptosis","volume":"4","author":"McMahon","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"djt369","DOI":"10.1093\/jnci\/djt369","article-title":"TGF-\u03b2: Duality of Function Between Tumor Prevention and Carcinogenesis","volume":"106","author":"Principe","year":"2014","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Satam, H., Joshi, K., Mangrolia, U., Waghoo, S., Zaidi, G., Rawool, S., Thakare, R.P., Banday, S., Mishra, A.K., and Das, G. (2023). Next-Generation Sequencing Technology: Current Trends and Advancements. Biology, 12.","DOI":"10.3390\/biology12070997"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"4","DOI":"10.20892\/j.issn.2095-3941.2018.0055","article-title":"Next-Generation Sequencing and Its Clinical Application","volume":"16","author":"Qin","year":"2019","journal-title":"Cancer Biol. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","article-title":"DNA Sequencing with Chain-Terminating Inhibitors","volume":"74","author":"Sanger","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.humimm.2021.02.012","article-title":"Next-Generation Sequencing Technologies: An Overview","volume":"82","author":"Hu","year":"2021","journal-title":"Hum. Immunol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrg2484","article-title":"RNA-Seq: A Revolutionary Tool for Transcriptomics","volume":"10","author":"Wang","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/bib\/bby051","article-title":"Review of Applications of High-Throughput Sequencing in Personalized Medicine: Barriers and Facilitators of Future Progress in Research and Clinical Application","volume":"20","author":"Lightbody","year":"2019","journal-title":"Brief. Bioinform."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature24286","article-title":"DNA Sequencing at 40: Past, Present and Future","volume":"550","author":"Shendure","year":"2017","journal-title":"Nature"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Beedanagari, S., and John, K. (2014). Next Generation Sequencing. Encyclopedia of Toxicology, Elsevier.","DOI":"10.1016\/B978-0-12-386454-3.00678-3"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41576-020-0236-x","article-title":"Long-Read Human Genome Sequencing and Its Applications","volume":"21","author":"Logsdon","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/nature07517","article-title":"Accurate Whole Human Genome Sequencing Using Reversible Terminator Chemistry","volume":"456","author":"Bentley","year":"2008","journal-title":"Nature"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1038\/s41588-023-01540-6","article-title":"Most Large Structural Variants in Cancer Genomes Can Be Detected without Long Reads","volume":"55","author":"Choo","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Bagger, F.O., Borgwardt, L., Jespersen, A.S., Hansen, A.R., Bertelsen, B., Kodama, M., and Nielsen, F.C. (2024). Whole Genome Sequencing in Clinical Practice. BMC Med. Genom., 17.","DOI":"10.1186\/s12920-024-01795-w"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/s41431-022-01113-x","article-title":"Recommendations for Whole Genome Sequencing in Diagnostics for Rare Diseases","volume":"30","author":"Souche","year":"2022","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"The Lancet Oncology (2024). Incorporating Whole-Genome Sequencing into Cancer Care. Lancet Oncol., 25, 945.","DOI":"10.1016\/S1470-2045(24)00401-7"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41588-024-01785-9","article-title":"Analysis of 10,478 Cancer Genomes Identifies Candidate Driver Genes and Opportunities for Precision Oncology","volume":"56","author":"Kinnersley","year":"2024","journal-title":"Nat. Genet."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/gim.2014.58","article-title":"The Usefulness of Whole-Exome Sequencing in Routine Clinical Practice","volume":"16","author":"Iglesias","year":"2014","journal-title":"Genet. Med."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/jhg.2013.114","article-title":"The Promise of Whole-Exome Sequencing in Medical Genetics","volume":"59","author":"Rabbani","year":"2014","journal-title":"J. Hum. Genet."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.molmed.2016.01.006","article-title":"Molecular Risk Factors for Schizophrenia","volume":"22","author":"Modai","year":"2016","journal-title":"Trends Mol. Med."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s12282-024-01628-9","article-title":"Applying Whole-Genome and Whole-Exome Sequencing in Breast Cancer: A Review of the Landscape","volume":"31","author":"Ganatra","year":"2024","journal-title":"Breast Cancer"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12967-018-1504-9","article-title":"Family Specific Genetic Predisposition to Breast Cancer: Results from Tunisian Whole Exome Sequenced Breast Cancer Cases","volume":"16","author":"Hamdi","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Pei, X.M., Yeung, M.H.Y., Wong, A.N.N., Tsang, H.F., Yu, A.C.S., Yim, A.K.Y., and Wong, S.C.C. (2023). Targeted Sequencing Approach and Its Clinical Applications for the Molecular Diagnosis of Human Diseases. Cells, 12.","DOI":"10.3390\/cells12030493"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.csbj.2019.10.004","article-title":"Applications and Analysis of Targeted Genomic Sequencing in Cancer Studies","volume":"17","author":"Palladino","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2015-05-647172","article-title":"Disease Evolution and Outcomes in Familial AML with Germline CEBPA Mutations","volume":"126","author":"Tawana","year":"2015","journal-title":"Blood"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41467-017-01470-y","article-title":"Prevalence and Detection of Low-Allele-Fraction Variants in Clinical Cancer Samples","volume":"8","author":"Shin","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nm.3886","article-title":"Subclonal Diversification of Primary Breast Cancer Revealed by Multiregion Sequencing","volume":"21","author":"Yates","year":"2015","journal-title":"Nat. Med."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Padma, V.V. (2015). An Overview of Targeted Cancer Therapy. BioMedicine, 5.","DOI":"10.7603\/s40681-015-0019-4"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"515","DOI":"10.46747\/cfp.6807515","article-title":"Targeted Cancer Therapies: Clinical Pearls for Primary Care","volume":"68","author":"Shuel","year":"2022","journal-title":"Can. Fam. Physician"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular Targeted Therapy for Anticancer Treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.21873\/anticanres.13476","article-title":"From \u2018Targeted Therapy\u2019 to Targeted Therapy","volume":"39","author":"PETERS","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mpmed.2015.10.012","article-title":"Targeted Therapy in Cancer","volume":"44","author":"Charlton","year":"2016","journal-title":"Medicine"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular Targeted Therapy: Treating Cancer with Specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1002\/mco2.181","article-title":"Small Molecule Inhibitors Targeting the Cancers","volume":"3","author":"Liu","year":"2022","journal-title":"MedComm"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.pharmthera.2013.11.011","article-title":"BRAF Inhibitors in Cancer Therapy","volume":"142","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour Micro-Environment Elicits Innate Resistance to RAF Inhibitors through HGF Secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.critrevonc.2015.08.004","article-title":"Dominant Mechanisms of Primary Resistance Differ from Dominant Mechanisms of Secondary Resistance to Targeted Therapies","volume":"97","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5603\/MRJ.a2019.0016","article-title":"Limitations of Molecularly Targeted Therapy","volume":"4","author":"Balik","year":"2019","journal-title":"Med. Res. J."},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Zahavi, D., and Weiner, L. (2020). Monoclonal Antibodies in Cancer Therapy. Antibodies, 9.","DOI":"10.3390\/antib9030034"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1574884712666170809124728","article-title":"Monoclonal Antibodies: A Review","volume":"13","author":"Singh","year":"2018","journal-title":"Curr. Clin. Pharmacol."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Kumar, M., Jalota, A., Sahu, S.K., and Haque, S. (2024). Therapeutic Antibodies for the Prevention and Treatment of Cancer. J. Biomed. Sci., 31.","DOI":"10.1186\/s12929-024-00996-w"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/ni.2939","article-title":"Type I and Type II Fc Receptors Regulate Innate and Adaptive Immunity","volume":"15","author":"Pincetic","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev-immunol-051116-052433","article-title":"Signaling by Antibodies: Recent Progress","volume":"35","author":"Bournazos","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"ref_229","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2021). Trastuzumab for Early-Stage, HER2-Positive Breast Cancer: A Meta-Analysis of 13,864 Women in Seven Randomised Trials. Lancet Oncol., 22, 1139\u20131150."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-Positive Breast Cancer: Advances and Future Directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer: Underlying Mechanisms and Reversal Strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/oncolo\/oyad262","article-title":"Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer","volume":"28","author":"Kasi","year":"2023","journal-title":"Oncologist"},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Gordeev, A., Vaal, A., Puchkova, M., Smirnova, I., Doronin, A., Znobishcheva, A., Zhmudanova, D., Aleksandrov, A., Sukchev, M., and Imyanitov, E. (2024). Preclinical Comparison of Prolgolimab, Pembrolizumab and Nivolumab. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-72118-3"},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"McMahon, D.J., McLaughlin, R., and Naidoo, J. (2024). Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review. Cancers, 16.","DOI":"10.3390\/cancers16030527"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 Blockers for Treatment of Cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"595","DOI":"10.21037\/atm.2019.05.58","article-title":"Immunotherapy and Targeted Therapy\u2014The New Roadmap in Cancer Treatment","volume":"7","author":"Shahid","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.21037\/tlcr-20-772","article-title":"Immunotherapy in Oncogene Addicted Non-Small Cell Lung Cancer","volume":"10","author":"McLean","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pccm.2024.08.002","article-title":"Overcoming EGFR-TKI Resistance by Targeting the Tumor Microenvironment","volume":"2","author":"Zhang","year":"2024","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"e24559","DOI":"10.1016\/j.heliyon.2024.e24559","article-title":"Potential Role of Immunotherapy and Targeted Therapy in the Treatment of Cancer: A Contemporary Nursing Practice","volume":"10","author":"Dailah","year":"2024","journal-title":"Heliyon"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41571-022-00718-x","article-title":"At the Crossroads of Immunotherapy for Oncogene-Addicted Subsets of NSCLC","volume":"20","author":"Otano","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in Cancer Treatment: A Review of 15 Years of Clinical Experience and Future Outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1053\/j.semnuclmed.2015.10.007","article-title":"Radioimmunotherapy for Treatment of Acute Leukemia","volume":"46","author":"Gaschet","year":"2016","journal-title":"Semin. Nucl. Med."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of Human Tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4103\/jcrt.JCRT_892_18","article-title":"Calculation of Radium-223 and Actinium-225 \u03b1-Emitter Radiopharmaceuticals Dose Rates in Treatment of Metastatic Castration-Resistant Prostate Cancer","volume":"17","author":"Abbasi","year":"2021","journal-title":"J. Cancer Res. Ther."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.2967\/jnumed.107.044016","article-title":"High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment","volume":"48","author":"Cremonesi","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2967\/jnumed.112.118539","article-title":"The Role of P53 in Combination Radioimmunotherapy with 64Cu-DOTA-Cetuximab and Cisplatin in a Mouse Model of Colorectal Cancer","volume":"54","author":"Guo","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody Drug Conjugate: The \u201cBiological Missile\u201d for Targeted Cancer Therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_248","doi-asserted-by":"crossref","unstructured":"Hurwitz, J., Haggstrom, L.R., and Lim, E. (2023). Antibody\u2013Drug Conjugates: Ushering in a New Era of Cancer Therapy. Pharmaceutics, 15.","DOI":"10.20944\/preprints202306.0232.v1"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/17512433.2018.1478725","article-title":"Gemtuzumab Ozogamicin for the Treatment of Acute Myeloid Leukemia","volume":"11","author":"Baron","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Gogia, P., Ashraf, H., Bhasin, S., and Xu, Y. (2023). Antibody\u2013Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence. Cancers, 15.","DOI":"10.3390\/cancers15153886"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global Manufacturing of CAR T Cell Therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"De Marco, R.C., Monzo, H.J., and Ojala, P.M. (2023). CAR T Cell Therapy: A Versatile Living Drug. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076300"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical Lessons Learned from the First Leg of the CAR T Cell Journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"2378543","DOI":"10.1080\/21645515.2024.2378543","article-title":"Approved CAR-T Therapies Have Reproducible Efficacy and Safety in Clinical Practice","volume":"20","author":"Waghela","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"lgz008","DOI":"10.1093\/jncimonographs\/lgz008","article-title":"Potential Successes and Challenges of Targeted Cancer Therapies","volume":"2019","author":"Keefe","year":"2019","journal-title":"JNCI Monogr."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","article-title":"Unveiling the Mechanisms and Challenges of Cancer Drug Resistance","volume":"22","author":"Khan","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_257","unstructured":"American Cancer Society (2025, March 05). Managing Cancer-Related Side Effects. Available online: https:\/\/www.cancer.org\/cancer\/managing-cancer\/side-effects.html."},{"key":"ref_258","doi-asserted-by":"crossref","unstructured":"Kiss, B., and Borb\u00e9ly, J. (2023). Business Risk Mitigation in the Development Process of New Monoclonal Antibody Drug Conjugates for Cancer Treatment. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15061761"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1038\/s41591-024-03231-z","article-title":"CAR-T and Cellular Gene Therapies Are Too Expensive","volume":"30","year":"2024","journal-title":"Nat. Med."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"100860","DOI":"10.1016\/j.ctarc.2024.100860","article-title":"Personalized Medicine: An Alternative for Cancer Treatment","volume":"42","author":"Singh","year":"2024","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_261","doi-asserted-by":"crossref","unstructured":"Hoeben, A., Joosten, E.A.J., and van den Beuken-van Everdingen, M.H.J. (2021). Personalized Medicine: Recent Progress in Cancer Therapy. Cancers, 13.","DOI":"10.3390\/cancers13020242"},{"key":"ref_262","doi-asserted-by":"crossref","unstructured":"Gambardella, V., Tarazona, N., Cejalvo, J.M., Lombardi, P., Huerta, M., Rosell\u00f3, S., Fleitas, T., Roda, D., and Cervantes, A. (2020). Personalized Medicine: Recent Progress in Cancer Therapy. Cancers, 12.","DOI":"10.3390\/cancers12041009"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12967-020-02316-w","article-title":"How Personalised Medicine Will Transform Healthcare by 2030: The ICPerMed Vision","volume":"18","author":"Vicente","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_264","doi-asserted-by":"crossref","unstructured":"Saeed, R.F., Awan, U.A., Saeed, S., Mumtaz, S., Akhtar, N., and Aslam, S. (2023). Targeted Therapy and Personalized Medicine. Therapeutic Approaches in Cancer Treatment, Springer.","DOI":"10.1007\/978-3-031-27156-4_10"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer Chemotherapy and beyond: Current Status, Drug Candidates, Associated Risks and Progress in Targeted Therapeutics","volume":"10","author":"Anand","year":"2023","journal-title":"Genes Dis."},{"key":"ref_266","doi-asserted-by":"crossref","unstructured":"Cecchin, E., and Stocco, G. (2020). Pharmacogenomics and Personalized Medicine. Genes, 11.","DOI":"10.3390\/genes11060679"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1124\/pharmrev.122.000810","article-title":"Pharmacogenomics: Driving Personalized Medicine","volume":"75","author":"Sadee","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the MTOR Signaling Network for Cancer Therapy","volume":"27","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.molcel.2021.03.031","article-title":"The Dynamic Mechanism of 4E-BP1 Recognition and Phosphorylation by MTORC1","volume":"81","author":"Imseng","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1535-7163.MCT-15-0720","article-title":"The Enigma of Rapamycin Dosage","volume":"15","author":"Mukhopadhyay","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid Biopsy in Cancer: Current Status, Challenges and Future Prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s43018-024-00756-7","article-title":"PERCEPTION Predicts Patient Response and Resistance to Treatment Using Single-Cell Transcriptomics of Their Tumors","volume":"5","author":"Sinha","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"102498","DOI":"10.1016\/j.ctrv.2022.102498","article-title":"Artificial Intelligence in Cancer Research and Precision Medicine: Applications, Limitations and Priorities to Drive Transformation in the Delivery of Equitable and Unbiased Care","volume":"112","author":"Corti","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-021-01105-2","article-title":"Applications of Single-Cell Sequencing in Cancer Research: Progress and Perspectives","volume":"14","author":"Lei","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1373\/clinchem.2017.283895","article-title":"Single-Cell Genomics","volume":"65","author":"Paolillo","year":"2019","journal-title":"Clin. Chem."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nmeth.3835","article-title":"Monovar: Single-Nucleotide Variant Detection in Single Cells","volume":"13","author":"Zafar","year":"2016","journal-title":"Nat. Methods"},{"key":"ref_277","doi-asserted-by":"crossref","unstructured":"Frumkin, D., Wasserstrom, A., Itzkovitz, S., Harmelin, A., Rechavi, G., and Shapiro, E. (2008). Amplification of Multiple Genomic Loci from Single Cells Isolated by Laser Micro-Dissection of Tissues. BMC Biotechnol., 8.","DOI":"10.1186\/1472-6750-8-17"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jim.2005.04.018","article-title":"Laser Capture Microdissection and Single-Cell RT-PCR without RNA Purification","volume":"302","author":"Keays","year":"2005","journal-title":"J. Immunol. Methods"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.molcel.2015.04.005","article-title":"The Technology and Biology of Single-Cell RNA Sequencing","volume":"58","author":"Kolodziejczyk","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nbt.2282","article-title":"Full-Length MRNA-Seq from Single-Cell Levels of RNA and Individual Circulating Tumor Cells","volume":"30","author":"Luo","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1101\/gr.110882.110","article-title":"Characterization of the Single-Cell Transcriptional Landscape by Highly Multiplex RNA-Seq","volume":"21","author":"Islam","year":"2011","journal-title":"Genome Res."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.celrep.2012.08.003","article-title":"CEL-Seq: Single-Cell RNA-Seq by Multiplexed Linear Amplification","volume":"2","author":"Hashimshony","year":"2012","journal-title":"Cell Rep."},{"key":"ref_283","doi-asserted-by":"crossref","unstructured":"Zhao, K., Li, Q., Li, P., Liu, T., Liu, X., Zhu, F., and Zhang, L. (2024). Single-Cell Transcriptome Sequencing Provides Insight into Multiple Chemotherapy Resistance in a Patient with Refractory DLBCL: A Case Report. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1303310"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular Subtypes of Diffuse Large B Cell Lymphoma Are Associated with Distinct Pathogenic Mechanisms and Outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","article-title":"Cancer-Related Inflammation and Treatment Effectiveness","volume":"15","author":"Diakos","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_288","doi-asserted-by":"crossref","unstructured":"Liu, M.-K., Liu, F., Dai, Y.-T., Weng, X.-Q., Cheng, L.-L., Fan, L.-Q., Liu, H., Jiang, L., Sun, X.-J., and Fang, H. (2023). Case Report: Molecular and Microenvironment Change upon Midostaurin Treatment in Mast Cell Leukemia at Single-Cell Level. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1210909"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.molcel.2018.08.040","article-title":"The Proto-Oncogene c-Kit Inhibits Tumor Growth by Behaving as a Dependence Receptor","volume":"72","author":"Wang","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2016.146563","article-title":"Advanced Systemic Mastocytosis: From Molecular and Genetic Progress to Clinical Practice","volume":"101","author":"Ustun","year":"2016","journal-title":"Haematologica"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"11214","DOI":"10.1093\/nar\/gky756","article-title":"Interplay between Transcription Regulators RUNX1 and FUBP1 Activates an Enhancer of the Oncogene c-KIT and Amplifies Cell Proliferation","volume":"46","author":"Debaize","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s13046-019-1330-9","article-title":"RUNX1 Promotes Tumour Metastasis by Activating the Wnt\/\u03b2-Catenin Signalling Pathway and EMT in Colorectal Cancer","volume":"38","author":"Li","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/bfgp\/elae013","article-title":"A Comprehensive Review of Machine Learning Techniques for Multi-Omics Data Integration: Challenges and Applications in Precision Oncology","volume":"23","author":"Acharya","year":"2024","journal-title":"Brief. Funct. Genom."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1089\/wound.2012.0379","article-title":"An Introduction to Functional Genomics and Systems Biology","volume":"2","author":"Bunnik","year":"2013","journal-title":"Adv. Wound Care"},{"key":"ref_295","doi-asserted-by":"crossref","unstructured":"Wu, X., Yang, X., Dai, Y., Zhao, Z., Zhu, J., Guo, H., and Yang, R. (2024). Single-Cell Sequencing to Multi-Omics: Technologies and Applications. Biomark. Res., 12.","DOI":"10.1186\/s40364-024-00643-4"},{"key":"ref_296","doi-asserted-by":"crossref","unstructured":"Chakraborty, S., Sharma, G., Karmakar, S., and Banerjee, S. (2024). Multi-OMICS Approaches in Cancer Biology: New Era in Cancer Therapy. Biochim. Biophys. Acta-Mol. Basis Dis., 1870.","DOI":"10.1016\/j.bbadis.2024.167120"},{"key":"ref_297","doi-asserted-by":"crossref","unstructured":"Cho, S.B. (2022). Uncovering Oncogenic Mechanisms of Tumor Suppressor Genes in Breast Cancer Multi-Omics Data. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179624"},{"key":"ref_298","doi-asserted-by":"crossref","unstructured":"Zhao, M., and Zhao, Z. (2016). Concordance of Copy Number Loss and Down-Regulation of Tumor Suppressor Genes: A Pan-Cancer Study. BMC Genom., 17.","DOI":"10.1186\/s12864-016-2904-y"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1101\/gr.268292.120","article-title":"Pan-Cancer Multi-Omics Analysis and Orthogonal Experimental Assessment of Epigenetic Driver Genes","volume":"30","author":"Halaburkova","year":"2020","journal-title":"Genome Res."},{"key":"ref_300","doi-asserted-by":"crossref","unstructured":"Schupp, P.G., Shelton, S.J., Brody, D.J., Eliscu, R., Johnson, B.E., Mazor, T., Kelley, K.W., Potts, M.B., McDermott, M.W., and Huang, E.J. (2024). Deconstructing Intratumoral Heterogeneity through Multiomic and Multiscale Analysis of Serial Sections. Cancers, 16.","DOI":"10.3390\/cancers16132429"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s43588-021-00086-z","article-title":"Undisclosed, Unmet and Neglected Challenges in Multi-Omics Studies","volume":"1","author":"Tarazona","year":"2021","journal-title":"Nat. Comput. Sci."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.7150\/thno.71144","article-title":"CRISPR-Cas9 Library Screening Approach for Anti-Cancer Drug Discovery: Overview and Perspectives","volume":"12","author":"Chan","year":"2022","journal-title":"Theranostics"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex Genome Engineering Using CRISPR\/Cas Systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"ref_304","first-page":"353","article-title":"Mechanism and Applications of CRISPR\/Cas-9-Mediated Genome Editing","volume":"15","author":"Asmamaw","year":"2021","journal-title":"Biologics"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity","volume":"154","author":"Ran","year":"2013","journal-title":"Cell"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"e2300688","DOI":"10.1200\/PO.23.00688","article-title":"Modeling Extraordinary Response Through Targeting Secondary Alterations in Fusion-Associated Sarcoma","volume":"8","author":"Vanoli","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/s41379-022-01023-9","article-title":"Comprehensive Genomic Profiling of EWSR1\/FUS::CREB Translocation-Associated Tumors Uncovers Prognostically Significant Recurrent Genetic Alterations and Methylation-Transcriptional Correlates","volume":"35","author":"Dermawan","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","article-title":"Current Applications and Future Perspective of CRISPR\/Cas9 Gene Editing in Cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1002\/jcp.30064","article-title":"CRISPR\/Cas Gene Therapy","volume":"236","author":"Zhang","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"113891","DOI":"10.1016\/j.addr.2021.113891","article-title":"Nanotechnology-Based Delivery of CRISPR\/Cas9 for Cancer Treatment","volume":"176","author":"Xu","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.semcancer.2023.01.006","article-title":"Artificial Intelligence in Lung Cancer Diagnosis and Prognosis: Current Application and Future Perspective","volume":"89","author":"Huang","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"ref_312","doi-asserted-by":"crossref","unstructured":"Chen, Y., Han, Q., Huang, Z., Lyu, M., Ai, Z., Liang, Y., Yan, H., Wang, M., and Xiang, Z. (2022). Value of IVIM in Differential Diagnoses between Benign and Malignant Solitary Lung Nodules and Masses: A Meta-Analysis. Front. Surg., 9.","DOI":"10.3389\/fsurg.2022.817443"},{"key":"ref_313","doi-asserted-by":"crossref","unstructured":"Wan, Y.-L., Wu, P., Huang, P.-C., Tsay, P.-K., Pan, K.-T., Trang, N., Chuang, W.-Y., Wu, C.-Y., and Lo, S. (2020). The Use of Artificial Intelligence in the Differentiation of Malignant and Benign Lung Nodules on Computed Tomograms Proven by Surgical Pathology. Cancers, 12.","DOI":"10.3390\/cancers12082211"},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"7826","DOI":"10.1002\/mp.15298","article-title":"3D Gray Density Coding Feature for Benign-malignant Pulmonary Nodule Classification on Chest CT","volume":"48","author":"Zheng","year":"2021","journal-title":"Med. Phys."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10278-020-00417-y","article-title":"Lung Nodule Classification Using Biomarkers, Volumetric Radiomics, and 3D CNNs","volume":"34","author":"Mehta","year":"2021","journal-title":"J. Digit. Imaging"},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1002\/mp.14445","article-title":"DICOM Re-encoding of Volumetrically Annotated Lung Imaging Database Consortium (LIDC) Nodules","volume":"47","author":"Fedorov","year":"2020","journal-title":"Med. Phys."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1118\/1.3528204","article-title":"The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI): A Completed Reference Database of Lung Nodules on CT Scans","volume":"38","author":"Armato","year":"2011","journal-title":"Med. Phys."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/s41591-018-0177-5","article-title":"Classification and Mutation Prediction from Non\u2013Small Cell Lung Cancer Histopathology Images Using Deep Learning","volume":"24","author":"Coudray","year":"2018","journal-title":"Nat. Med."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ucl.2023.06.006","article-title":"Genomics and Artificial Intelligence","volume":"51","author":"Wong","year":"2024","journal-title":"Urol. Clin. N. Am."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"110474","DOI":"10.1016\/j.ygeno.2022.110474","article-title":"Epigenome-Wide DNA Methylation and Transcriptome Profiling of Localized and Locally Advanced Prostate Cancer: Uncovering New Molecular Markers","volume":"114","author":"Liu","year":"2022","journal-title":"Genomics"},{"key":"ref_322","doi-asserted-by":"crossref","unstructured":"Armakolas, A., Kotsari, M., and Koskinas, J. (2023). Liquid Biopsies, Novel Approaches and Future Directions. Cancers, 15.","DOI":"10.3390\/cancers15051579"},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12967-023-03960-8","article-title":"Liquid Biopsies: The Future of Cancer Early Detection","volume":"21","author":"Connal","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/ijc.11596","article-title":"Quantification of Cytokeratin 20, Carcinoembryonic Antigen and Guanylyl Cyclase C MRNA Levels in Lymph Nodes May Not Predict Treatment Failure in Colorectal Cancer Patients","volume":"108","author":"Bustin","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-17-1181","article-title":"ESR1 Methylation: A Liquid Biopsy\u2013Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment","volume":"24","author":"Mastoraki","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An Ultrasensitive Method for Quantitating Circulating Tumor DNA with Broad Patient Coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat. Med."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid Biopsy: Current Technology and Clinical Applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-023-01715-z","article-title":"Clinical Application and Detection Techniques of Liquid Biopsy in Gastric Cancer","volume":"22","author":"Ma","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_329","doi-asserted-by":"crossref","unstructured":"(2024). Turning the Tide of Early Cancer Detection. Nat. Med., 30, 1217.","DOI":"10.1038\/s41591-024-03046-y"},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5230\/jgc.2024.24.e5","article-title":"Liquid Biopsy: An Emerging Diagnostic, Prognostic, and Predictive Tool in Gastric Cancer","volume":"24","author":"Han","year":"2024","journal-title":"J. Gastric Cancer"},{"key":"ref_331","doi-asserted-by":"crossref","unstructured":"Fatima, S., Ma, Y., Safrachi, A., Haider, S., Spring, K.J., Vafaee, F., Scott, K.F., Roberts, T.L., Becker, T.M., and de Souza, P. (2022). Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy. Cancers, 14.","DOI":"10.3390\/cancers14071669"},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nm0715-827b","article-title":"Erratum: Clonal Evolution and Resistance to EGFR Blockade in the Blood of Colorectal Cancer Patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat. Med."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"239","DOI":"10.37349\/etat.2020.00015","article-title":"Future Directions and Management of Liquid Biopsy in Non-Small Cell Lung Cancer","volume":"1","author":"Cossu","year":"2020","journal-title":"Explor. Target. Anti-Tumor Ther."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.21037\/tlcr.2019.09.15","article-title":"Role of Liquid Biopsy in Oncogene-Addicted Non-Small Cell Lung Cancer","volume":"8","author":"Canale","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid Biopsy and Minimal Residual Disease\u2014Latest Advances and Implications for Cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_336","doi-asserted-by":"crossref","unstructured":"Johnston, A.D., Ross, J.P., Ma, C., Fung, K.Y.C., and Locke, W.J. (2023). Epigenetic Liquid Biopsies for Minimal Residual Disease, What\u2019s around the Corner?. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1103797"},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal Residual Disease as a Target for Liquid Biopsy in Patients with Solid Tumours","volume":"22","author":"Pantel","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_338","doi-asserted-by":"crossref","unstructured":"Alba-Bernal, A., Lavado-Valenzuela, R., Dom\u00ednguez-Recio, M.E., Jim\u00e9nez-Rodriguez, B., Queipo-Ortu\u00f1o, M.I., Alba, E., and Comino-M\u00e9ndez, I. (2020). Challenges and Achievements of Liquid Biopsy Technologies Employed in Early Breast Cancer. eBioMedicine, 62.","DOI":"10.1016\/j.ebiom.2020.103100"},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","article-title":"Liquid Biopsy: A Step Closer to Transform Diagnosis, Prognosis and Future of Cancer Treatments","volume":"21","author":"Lone","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The Tumor Microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic Cancer Vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_342","doi-asserted-by":"crossref","unstructured":"Mollica Poeta, V., Massara, M., Capucetti, A., and Bonecchi, R. (2019). Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00379"},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12935-024-03518-8","article-title":"The Axis of Tumor-Associated Macrophages, Extracellular Matrix Proteins, and Cancer-Associated Fibroblasts in Oncogenesis","volume":"24","author":"Yu","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_344","doi-asserted-by":"crossref","unstructured":"Czekay, R.-P., Cheon, D.-J., Samarakoon, R., Kutz, S.M., and Higgins, P.J. (2022). Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets. Cancers, 14.","DOI":"10.3390\/cancers14051231"},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","article-title":"Modulation of the Tumor Microenvironment and Mechanism of Immunotherapy-Based Drug Resistance in Breast Cancer","volume":"23","author":"Kundu","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_346","doi-asserted-by":"crossref","unstructured":"Kaczmarek, M., Pozna\u0144ska, J., Fechner, F., Michalska, N., Paszkowska, S., Napiera\u0142a, A., and Mackiewicz, A. (2023). Cancer Vaccine Therapeutics: Limitations and Effectiveness\u2014A Literature Review. Cells, 12.","DOI":"10.3390\/cells12172159"},{"key":"ref_347","unstructured":"Memorial Sloan Kettering Cancer Center (2025, January 25). Cancer Vaccines: The Types, How They Work, and Which Cancers They Treat. Available online: https:\/\/www.mskcc.org\/cancer-care\/diagnosis-treatment\/cancer-treatments\/immunotherapy\/cancer-vaccines."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer Vaccines as Promising Immuno-Therapeutics: Platforms and Current Progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"MRNA Vaccine for Cancer Immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41416-023-02327-6","article-title":"Whole Tumour Cell-Based Vaccines: Tuning the Instruments to Orchestrate an Optimal Antitumour Immune Response","volume":"129","author":"Gleisner","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12032-023-02060-3","article-title":"The Future of Cancer Immunotherapy: DNA Vaccines Leading the Way","volume":"40","author":"Pandya","year":"2023","journal-title":"Med. Oncol."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41585-023-00739-w","article-title":"Vaccines as Treatments for Prostate Cancer","volume":"20","author":"Rastogi","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1586\/erv.10.173","article-title":"Sipuleucel-T: Harbinger of a New Age of Therapeutics for Prostate Cancer","volume":"10","author":"Madan","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_354","doi-asserted-by":"crossref","unstructured":"Han, J., Gu, X., Li, Y., and Wu, Q. (2020). Mechanisms of BCG in the Treatment of Bladder Cancer-Current Understanding and the Prospect. Biomed. Pharmacother., 129.","DOI":"10.1016\/j.biopha.2020.110393"},{"key":"ref_355","doi-asserted-by":"crossref","unstructured":"Jiang, S., and Redelman-Sidi, G. (2022). BCG in Bladder Cancer Immunotherapy. Cancers, 14.","DOI":"10.3390\/cancers14133073"},{"key":"ref_356","doi-asserted-by":"crossref","unstructured":"Cheng, L., Wang, Y., and Du, J. (2020). Human Papillomavirus Vaccines: An Updated Review. Vaccines, 8.","DOI":"10.3390\/vaccines8030391"},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"100780","DOI":"10.1016\/j.ctarc.2023.100780","article-title":"Human Papilloma Virus Vaccines: A Comprehensive Narrative Review","volume":"37","author":"Aggarwal","year":"2023","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_358","doi-asserted-by":"crossref","unstructured":"Flores, J.E., Thompson, A.J., Ryan, M., and Howell, J. (2022). The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma. Vaccines, 10.","DOI":"10.3390\/vaccines10050793"},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"215652","DOI":"10.1016\/j.canlet.2022.215652","article-title":"Long Term Outcome of Prevention of Liver Cancer by Hepatitis B Vaccine: Results from an RCT with 37 Years","volume":"536","author":"Cao","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic Viruses: A New Class of Immunotherapy Drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/mt.2010.140","article-title":"Targeting Localized Immune Suppression Within the Tumor Through Repeat Cycles of Immune Cell-Oncolytic Virus Combination Therapy","volume":"18","author":"Thorne","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41419-020-2236-3","article-title":"Characterization of Virus-Mediated Immunogenic Cancer Cell Death and the Consequences for Oncolytic Virus-Based Immunotherapy of Cancer","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_363","doi-asserted-by":"crossref","unstructured":"Guo, Z.S., Liu, Z., and Bartlett, D.L. (2014). Oncolytic Immunotherapy: Dying the Right Way Is a Key to Eliciting Potent Antitumor Immunity. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00074"},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12935-024-03424-z","article-title":"Enhancing Cancer Therapy: The Integration of Oncolytic Virus Therapy with Diverse Treatments","volume":"24","author":"Yan","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12943-022-01664-z","article-title":"Improving Cancer Immunotherapy by Rationally Combining Oncolytic Virus with Modulators Targeting Key Signaling Pathways","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic Virus Immunotherapy: Future Prospects for Oncology","volume":"6","author":"Raja","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_367","doi-asserted-by":"crossref","unstructured":"Ferrucci, P.F., Pala, L., Conforti, F., and Cocorocchio, E. (2021). Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13061383"},{"key":"ref_368","doi-asserted-by":"crossref","unstructured":"Peter, M., and K\u00fchnel, F. (2020). Oncolytic Adenovirus in Cancer Immunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12113354"},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic Viruses for Cancer Immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ccell.2018.03.011","article-title":"Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines","volume":"33","author":"Russell","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic Cancer Vaccines: Advancements, Challenges and Prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol. Ther.-Oncolytics"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/6\/1008\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:55:03Z","timestamp":1760028903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/6\/1008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":372,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["cancers17061008"],"URL":"https:\/\/doi.org\/10.3390\/cancers17061008","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]}}}